Clinical trials for professionals
Learn about our available clinical trials
-
2 de march de 2021MultisedeIn recruitment
INCB 18424-308 Trial to evaluate the long-term efficacy and safety of ruxolitinib cream in participants with vitiligo.
The purpose of this study is to further evaluate the effect and safety of ruxolitinib cream in people and their vitiligo with long-term use, as well as to evaluate how long the effect lasts in people who discontinue use of ruxolitinib cream. -
2 de march de 2021MadridIn recruitment
IVER-303 Trial of Ivermectin for three consecutive days to prevent SARS-Cov2 (COVID-19) related hospitalization in adults over 50 years of age.
The aim of this clinical research trial is to test whether Ivermectin can help patients with COVID-19 and what side effects it causes. -
23 de february de 2021PamplonaIn recruitment
-
22 de february de 2021PamplonaIn recruitment
ASTARTÉ Trial of Temocillin vs meropenem for the treatment of bacteremia caused by Enterobacteriaceae resistant to third generation cephalosporins.
The main objective of the study in which he is proposed to participate is to prove whether temocillin is as effective and safe as carbapenems in this type of infections, i.e., to demonstrate that its effect is as beneficial as carbapenems and that it does not produce more side effects. -
22 de february de 2021In recruitment
GCT1042-01 Trial to evaluate the safety of GEN1042 in subjects with malignant solid tumors.
The aim of the trial is to test whether GEN1042 is useful against certain types of solid tumor cancers. -
22 de february de 2021PamplonaIn recruitment
WO39608 Study of multiple immunotherapy-based treatment combinations in patients with metastatic pancreatic ductal adenocarcinoma.
The purpose of this study is to compare the effects, good or bad, on the patient and on pancreatic cancer of combinations of ATIs and conventional treatment in order to find out which treatment is best. ATI combinations are experimental drug treatments, which means that they are not approved by the health authorities for the treatment of pancreatic cancer. -
22 de february de 2021PamplonaIn recruitment
AB15003 Clinical trial to compare the efficacy and safety of masitinib and placebo in the treatment of patients with severe indolent or latent systemic mastocytosis with disability, unresponsive to optimal symptomatic treatment.
The objective of this study is to compare the efficacy and safety of an experimental drug, masitinib, administered orally at 3 mg/kg/day with a switch after 4 weeks of treatment to 4.5 mg/kg/day and another switch after 4 weeks of treatment to 6 mg/kg/day (all switches will be subject to toxicity monitoring) versus placebo in the treatment of patients with severe indolent or latent systemic mastocytosis with disability, unresponsive to symptomatic treatment. Masitinib will be taken twice daily o... -
22 de february de 2021PamplonaIn recruitment
D2440GBM1 Phase I trial of the oncolytic adenovirus DNX-2440 in patients with recurrent glioblastoma.
The main objective of this trial is to test whether the DNX2440 virus is safe. The research is aimed at adults with recurrent glioblastoma (patients already treated for the tumor in whom it has developed again). -
15 de february de 2021PamplonaIn recruitment
64007957MMY1003 T-cell trial, Talquetamab and Teclistamab, in subjects with relapsed or refractory multiple myeloma.
The objective of this study is to find a safe and tolerable dose and administration schedule for the combined administration of 2 study drugs, talquetamab (also known as JNJ-64407564) and teclistamab (also known as JNJ-64007957). This study drug combination will be administered to patients with multiple myeloma who have experienced progression after receiving baseline or licensed therapy. A dose is the amount of a drug that can be administered at one time. A dosing schedule is the frequency with... -
15 de february de 2021PamplonaIn recruitment
FS222-19101 Trial to evaluate the safety and antitumor activity of FS222, a bispecific antibody against CD137/PD-L1, in subjects with advanced malignancies.
The goal is to determine whether FS222 is safe in the treatment of cancer and the degree to which a person tolerates the side effects.